Diabetes News

AHA and ADA: CV Risk Assessment, Monitoring Essential for Patients with Type 1 Diabetes

Posted by dlife on Mon, Aug 25, 14, 12:42 PM 0 Comment

August 25, 2014 (Healio) - A greater understanding of the pathophysiology, risk prediction and treatment of CVD in patients with type 1 diabetes is essential to minimize the impact of these interrelated conditions, according to a new scientific statement from the American Heart Association and American Diabetes Association.

"CVD is a long-term complication of type 1 diabetes that is a major concern for patients and health care providers. ? Despite the known higher risk of CVD in individuals with type 1 diabetes mellitus, the pathophysiology underlying the relationship between CV events, CVD risk factors and type 1 diabetes is not well understood," the authors wrote in Diabetes Care.

The statement reviews the current knowledge about the relationship between type 1 diabetes and CVDs including CHD, cerebrovascular disease and peripheral artery disease. It clarifies the definition of type 1 diabetes, discusses the latest approaches to monitoring, diagnosis and treatment, provides in-depth epidemiological data, and more.

Risk factors

Risk factors important to CVD in patients with type 1 diabetes that could be important potential targets for risk reduction include:

Lipid levels.
Diabetes duration.
Unhealthy behaviors, including diet, exercise and smoking status.

Pediatric patients should receive particular attention, as "CVD risk factors are more common in children with type 1 diabetes than in the general pediatric population," according to the statement.

"More aggressive management of CVD risk factors and of the disease itself is likely to have a positive effect on CVD event rates," the authors wrote.

Monitoring and screening

Risk-prediction algorithms for CVD are not widely used for patients with type 1 diabetes. Approaches to the assessment of CVD burden in this patient population may include applying the same CHD risk-assessment and diagnostic strategies as are used in the general population, according to the statement.

While routine stress testing is not recommended for patients with type 1 diabetes, additional testing is recommended for any patient with symptoms suggestive of CHD. Further, advanced testing may be useful in patients with type 1 diabetes, according to the statement. Although data are lacking, a coronary artery calcium (CAC) assessment for risk prediction in patients with type 1 diabetes may be helpful. "It is reasonable to apply the current guidelines for the use of CAC assessment in type 1 diabetes, as recommended for the general population," the authors wrote.

Other testing modalities for CVD may be less useful, such as the evaluation of endothelial dysfunction by flow-mediated dilation and/or brachial artery reactivity or cardiac magnetic resonance imaging.

The following screening schedules for CVD risk factors are recommended for patients with type 1 diabetes: hyperglycemia (HbA1c, glucose monitoring), every 3 months; diabetic kidney disease (urine albumin to creatinine ratio, estimated glomerular filtration rate), annually, starting at 5 years after diagnosis; dyslipidemia (fasting lipid profile), every 2 years for adults and every 3 to 5 years for children aged 10 to 21 years; hypertension, each visit; prehypertension, each visit.

Opportunities remain

The authors also address areas in which the understanding of CVD in patients with type 1 diabetes is lacking. However, they acknowledge that "many of these data may be historical and that better glycemic control is changing the landscape of atherosclerosis in type 1 diabetes."

Specific areas worthy of attention include the understanding of cellular and molecular pathophysiology in CVD and type 1 diabetes; the development of atherosclerotic lesions and the natural history; the role of inflammatory markers; tests for preclinical disease; novel biomarkers; safe and effective pharmacological approaches; the best lifestyle modifications.

"Much work remains to be done to improve our understanding of type 1 diabetes and to help ameliorate the CVD effects of this important disease," the authors wrote.

Email this

Sign up for FREE dLife Newsletters

dLife Membership is FREE! Get exclusive access, free recipes, newsletters, savings, and much more! FPO

You are subscribed!
You are subscribed!
You are subscribed!
Sponsor Specials

dLife Weekly Poll

Do you have all the doctors you need on your diabetes care team?

  • Watch dLifeTV online now!

    Click here for more info